Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1703 Phase 1 Dose-Escalation in Healthy Caucasians
NCT04855591Phase 1Terminated
- Sponsor
- Atridia Pty Ltd
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1703 in asthma (4 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Adverse events at 34 weeks. Started Jun 2021; status: terminated.
02
Drugs
SHR-1703
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04855591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855591.